Ratings by Scotiabank (Greg Harrison)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/7/2025 | Travere Therapeutics | TVTX | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 8/6/2025 | BridgeBio Pharma | BBIO | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 8/6/2025 | Ocular Therapeutix | OCUL | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 8/5/2025 | Vertex | VRTX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 8/1/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 7/30/2025 | Apellis Pharmaceuticals | APLS | Maintain | Sector Perform (N/A) |
|
Details | ||
| 7/28/2025 | Agios Pharma | AGIO | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 7/14/2025 | Gossamer Bio Inc. | GOSS | New Coverage | Sector Outperform (N/A) |
1.36 (0.17) |
-87.5% | Details | |
| 7/2/2025 | Arcturus Therapeutics | ARCT | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 6/3/2025 | Vera Therapeutics | VERA | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 5/28/2025 | Liquidia Technologies | LQDA | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 5/28/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 5/28/2025 | Arcturus Therapeutics | ARCT | New Coverage | Sector Outperform (N/A) |
12.03 (7.53) |
-37.41% | Details | |
| 5/21/2025 | Vertex | VRTX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 5/21/2025 | Liquidia Technologies | LQDA | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 5/8/2025 | Geron Corporation | GERN | Downgrade | Sector Perform (Sector Outperform) |
1.31 (1.26) |
-3.82% | Details | |
| 5/6/2025 | Vertex | VRTX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 5/5/2025 | Liquidia Technologies | LQDA | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 5/2/2025 | Agios Pharma | AGIO | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 4/30/2025 | BridgeBio Pharma | BBIO | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 3/31/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 3/21/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 3/20/2025 | Liquidia Technologies | LQDA | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 3/10/2025 | Beam Therapeutics Inc | BEAM | Upgrade | Sector Outperform (Sector Perform) |
28.48 (34.14) |
19.87% | Details | |
| 3/3/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 3/3/2025 | Disc Medicine | IRON | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 3/3/2025 | Beam Therapeutics Inc | BEAM | Maintain | Sector Perform (N/A) |
|
Details | ||
| 2/27/2025 | Geron Corporation | GERN | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 2/21/2025 | BridgeBio Pharma | BBIO | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 2/12/2025 | BridgeBio Pharma | BBIO | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 2/12/2025 | Travere Therapeutics | TVTX | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 2/11/2025 | Vertex | VRTX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 1/31/2025 | Vertex | VRTX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 1/21/2025 | Disc Medicine | IRON | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 1/16/2025 | Keros Therapeutics | KROS | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 12/23/2024 | Vertex | VRTX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 11/25/2024 | BridgeBio Pharma | BBIO | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 11/15/2024 | BridgeBio Pharma | BBIO | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 11/6/2024 | Apellis Pharmaceuticals | APLS | Maintain | Sector Perform (N/A) |
|
Details | ||
| 11/5/2024 | Disc Medicine | IRON | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 11/5/2024 | Vertex | VRTX | Maintain | Sector Perform (N/A) |
|
Details | ||
| 11/1/2024 | Travere Therapeutics | TVTX | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 11/1/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 11/1/2024 | Agios Pharma | AGIO | Maintain | Sector Outperform (N/A) |
|
Details | ||
| 10/16/2024 | Vertex | VRTX | New Coverage | Sector Perform (N/A) |
484.30 (429.22) |
-11.37% | Details | |
| 10/16/2024 | Vera Therapeutics | VERA | New Coverage | Sector Outperform (N/A) |
40.21 (35.09) |
-12.73% | Details | |
| 10/16/2024 | Rocket Pharmaceuticals | RCKT | New Coverage | Sector Outperform (N/A) |
16.68 (3.35) |
-79.92% | Details | |
| 10/16/2024 | Travere Therapeutics | TVTX | New Coverage | Sector Outperform (N/A) |
17.69 (55.15) |
211.76% | Details | |
| 10/16/2024 | Ocular Therapeutix | OCUL | New Coverage | Sector Outperform (N/A) |
10.23 (9.43) |
-7.82% | Details | |
| 10/16/2024 | Liquidia Technologies | LQDA | New Coverage | Sector Outperform (N/A) |
11.38 (71.07) |
524.52% | Details | |
| 10/16/2024 | Disc Medicine | IRON | New Coverage | Sector Outperform (N/A) |
47.64 (70.79) |
48.59% | Details | |
| 10/16/2024 | Keros Therapeutics | KROS | New Coverage | Sector Outperform (N/A) |
60.39 (10.65) |
-82.36% | Details | |
| 10/16/2024 | Geron Corporation | GERN | New Coverage | Sector Outperform (N/A) |
4.19 (1.26) |
-69.93% | Details | |
| 10/16/2024 | BridgeBio Pharma | BBIO | New Coverage | Sector Outperform (N/A) |
25.38 (66.27) |
161.11% | Details | |
| 10/16/2024 | EyePoint Pharmaceuticals, Inc. | EYPT | New Coverage | Sector Outperform (N/A) |
9.88 (13.58) |
37.45% | Details | |
| 10/16/2024 | Beam Therapeutics Inc | BEAM | New Coverage | Sector Perform (N/A) |
26.34 (28.48) |
8.12% | Details | |
| 10/16/2024 | Apellis Pharmaceuticals | APLS | New Coverage | Sector Perform (N/A) |
27.95 (41.03) |
46.8% | Details | |
| 10/16/2024 | Alnylam Pharmaceuticals | ALNY | New Coverage | Sector Outperform (N/A) |
287.36 (278.09) |
-3.23% | Details | |
| 10/16/2024 | Agios Pharma | AGIO | New Coverage | Sector Outperform (N/A) |
42.04 (34.16) |
-18.74% | Details |
